---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-006125"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:51:23.238170+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rallybio reports FY2022 net loss of $66.7M; RLYB212 achieves proof-of-concept in Phase 1b

## Summary
- Net loss for FY2022 was $66.7M ($2.09/share) vs $47.0M ($1.84/share) in 2021; Q4 loss $16.2M.
- RLYB212 Phase 1b proof-of-concept: single dose eliminated >90% of HPA-1a positive platelets; well-tolerated.
- Cash, equivalents, and marketable securities $169.0M as of Dec 31, 2022; runway into Q1 2025.
- RLYB211 discontinued; RLYB212 multi-dose cohort initiated, data expected Q4 2023.
- Jonathan Lieber appointed CFO effective Feb 1, 2023; follow-on offering raised ~$55M in Nov 2022.

## SEC filing metadata
- accession: 0000950170-23-006125
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000095017023006125/0000950170-23-006125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000095017023006125/rlyb-20230306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-006125
- JSON: https://secwatch.observer/filing/0000950170-23-006125.json
- Plain text: https://secwatch.observer/filing/0000950170-23-006125.txt

## Key facts
- Earnings Releases
  Rallybio Corp reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On March 6, 2023, Rallybio Corporation issued a press release announcing its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739410/000095017023006125/0000950170-23-006125-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.